Bioqube Ventures is a specialist life sciences investment firm. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.
Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.
… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.
… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures.
… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.
Bioqube Ventures launched in 2020 its first independent fund “Bioqube Factory Fund I”.
… An early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.
… A fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures.
… A hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.
Location: Belgium, Brussels-Capital, City of Brussels
Employees: 11-50
Founded date: 2015
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A; Series B
Portfolio 11
| Date | Name | Website | Total Raised | Location |
| 10.07.2025 | Actithera | actithera.com | $75.5M | Norway |
| 15.02.2025 | Spica Ther... | spicatx.com | $12.59M | - |
| 26.07.2024 | Catalym | catalym.com | $261.12M | Germany, B... |
| 13.05.2024 | Commit Bio... | commitbio.com | $46.97M | - |
| 13.05.2024 | SynOx Ther... | synoxtherapeutics.com | $323.8M | Ireland, D... |
| 02.05.2023 | Anavo Ther... | anavotx.com | $85.32M | Netherland... |
| 06.03.2023 | Bicara The... | bicara.com | $635M | - |
| 15.10.2022 | Tridek One | tridekone.com | $17.42M | France, Il... |
| - | Primmune T... | primmunerx.com | $15.4M | United Sta... |
| - | Egle Thera... | egle-tx.com | $10.54M | France, Il... |
Show more
Persons 19
| Date | First Name | Last Name | Title | Location | |||
| - | Debora | Dumont | Managing P... | linkedin.c... | - | - | - |
| - | Olivier | Houben | - | linkedin.c... | - | - | - |
| - | Jon | Edwards | - | linkedin.c... | - | j*n@redtre... | - |
| - | Tom | Heyman | - | - | - | - | |
| - | Alexander | Demoulin | Associate | linkedin.c... | - | - | - |
| - | Joris | Vanderloch... | Chief Scie... | linkedin.c... | - | - | - |
| - | Tol | Trimborn | - | linkedin.c... | - | - | - |
| - | Jacques | Mizrahi | - | linkedin.c... | - | - | - |
| - | Joris | De Maeyer | Executive ... | linkedin.c... | - | - | - |
| - | Clement | Salque | Junior Ass... | linkedin.c... | - | - | - |
Show more
News 53
| Date | Title | Description |
| 06.06.2025 | Egle Therapeutics to Present Clinical Trial Progress Poster on Phase I/II EGL-121 Study for EGL-001 at 2025 ASCO Annual Meeting | Paris, France, May 30th 2025 – Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced a poster presentation at the upc... |
| 12.05.2025 | CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 | MUNICH–(BUSINESS WIRE)–CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage antibody visugromab can improve the anti-tumor activity of antibody-drug conjugates (ADCs). The da... |
| 12.05.2025 | Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting | PARIS–(BUSINESS WIRE)–Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the American Association for ... |
| 24.04.2025 | SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy | Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercializat... |
| 24.04.2025 | Commit Biologics announces €5.5m seed financing extension investment by Korys to further develop its Bispecific Complement Engaging (BiCE™) platform | Aarhus, Denmark, 28 January 2025, Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces a €5.5m extension to its seed financing. The contribution from new i... |
| 24.04.2025 | SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) | DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) — SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today ... |
| 24.04.2025 | Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030 | Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects ... |
| 22.01.2025 | Bioqube Ventures Unveils Spica Therapeutics to Pioneer Macrophage-Subset Targeted Therapies | Brussels, Belgium, January 9, 2025 – Spica Therapeutics (“Spica”), a pioneering biotech company focused on macrophage biology, today announced its emergence from stealth mode, supported by Bioqube Ventures. Headquartered in Belgium, with a ... |
| 15.01.2025 | Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors | Aarhus, Denmark, 8 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors... |
| 15.01.2025 | Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer | Paris, France, January 13, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of... |
Show more
Mentions in press and media 8
| Date | Title | Description |
| 30.01.2026 | Primmune Therapeutics Raises $8.6M in Additional Series B Funding | Primmune Therapeutics, a Carlsbad, CA-based clinical-stage therapeutics company, raised $8.6M in additional Series B funding. Backers included Bioqube Ventures, Oberland Capital and Samsara Biocapital. The raise brought the total of Series ... |
| 16.09.2025 | CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development | Experienced executives, Clinton Musil, Sujata Rao, MD, Heike Krupka, PhD, and Andrea Goddard join CatalYm to broaden and accelerate clinical programs into late-stage development Munich, Germany and San Francisco, USA, September 15, 2025 – C... |
| 14.07.2025 | Actithera Secures $75.5 Million to Propel Precision Radioligand Therapies | Actithera, a cutting-edge biotech firm, recently secured $75.5 million in oversubscribed Series A funding. This significant capital injection powers their precision radioligand therapy (RLT) initiatives. Funds will advance their lead FAP as... |
| 10.07.2025 | Actithera: $75.5 Million Series A Raised For Transforming Precision Radioligand Therapy | Actithera, a biotech company specializing in radiopharmaceuticals, has secured $75.5 million in an oversubscribed Series A financing round. This funding will help advance their lead FAP (Fibroblast Activation Protein) asset into clinical de... |
| 09.07.2025 | Actithera Raises $75.5M in Series A Funding | Actithera, an Oslo, Norway-, and Cambridge, MA-based radiopharmaceutical biotech company developing radioligand therapies (RLTs), raised $75.5M in Series A funding. The round was led by M Ventures and new investors Hadean Ventures, Sofinnov... |
| 03.05.2023 | Dutch-based Anavo Therapeutics secures €8.5M to systematically drug phosphatases: Know more | Leiden-based Anavo Therapeutics, a company that claims to be the first to systematically drug phosphatases – a rich target space previously considered undruggable for decades, announced that it has raised €8.5M in a Seed extension round of ... |
| 16.09.2022 | French biotech Tridek-One gets €16 million booster to restore the immune balance in patients | Paris-based biotech startup Tridek-One has raised €16 million in funding to speed up its research and development of CD31 agonists to restore the immune balance. The round was led by the Swiss VC Pureos Bioventures with the participation of... |
| 22.10.2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers About Egle Therapeutics About LSP About Bpifrance – InnoBio 2 About Tak... | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |